LivaNova (NSDQ:LIVN) said recently that it is ending its Caisson Interventional transcatheter mitral valve replacement (TMVR) program and plans to restructure its heart valve business to improve profitability. The company’s heart valve business represented nearly $130 million in revenue during fiscal 2018 and saw its revenue numbers decline over … [Read more...] about LivaNova pulls the plug on transcatheter mitral valve repair device
